Analyst Consensus ?
ConsensusBuy26 ratings
Bullish2492.3%
Neutral27.7%
Bearish00.0%
FN2 Earnings Intelligence
Ascendis Pharma A/S analyst ratings
Ascendis Pharma A/S (ASND) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$239.18Current
$136Low
$272.3Average
$344High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 21, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 15, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Sep 2, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Sep 1, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 31, 2026 |
| Jefferies | Buy | Buy | Maintain | Aug 31, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Aug 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Aug 31, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 14, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | May 15, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 8, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Oct 13, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 9, 2025 |
| UBS | Buy | Buy | Maintain | Aug 8, 2025 |
| Citigroup | Buy | Buy | Maintain | Aug 8, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2025 |
| Credit Suisse | Neutral | Neutral | Maintain | Apr 28, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Jan 17, 2023 |
| Cowen & Co. | Perform | Market Perform | Maintain | Jan 6, 2022 |
| Canaccord Genuity | Buy | Buy | Maintain | Jun 1, 2021 |
| Berenberg | Buy | Buy | Maintain | Dec 17, 2020 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Jan 24, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Aug 30, 2018 |
| Bank of America | Buy | Buy | Maintain | Jan 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $239.18. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $344 | $239.77 | +43.8% | Sep 16, 2026 |
| Raymond James | Martin Auster | $287 | $264.92 | +20.0% | Sep 15, 2026 |
| H.C. Wainwright | Analyst unavailable | $344 | $260.81 | +43.8% | Sep 10, 2026 |
| Oppenheimer | Leland Gershell | $312 | $260.25 | +30.4% | Sep 1, 2026 |
| Morgan Stanley | Maxwell Skor | $273 | $263.04 | +14.1% | Sep 1, 2026 |
| Jefferies | Analyst unavailable | $330 | $265.26 | +38.0% | Aug 31, 2026 |
| Stifel Nicolaus | Analyst unavailable | $326 | $265.32 | +36.3% | Aug 31, 2026 |
| UBS | Analyst unavailable | $345 | $247.91 | +44.2% | Aug 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $345 | $250.25 | +44.2% | Aug 27, 2026 |
| BMO Capital | Analyst unavailable | $319 | $248.85 | +33.4% | Aug 18, 2026 |
| RBC Capital | Luca Issi | $290 | $247.06 | +21.2% | Aug 14, 2026 |
| Barclays | Analyst unavailable | $329 | $246.23 | +37.6% | Aug 14, 2026 |
| Jefferies | Kelly Shi | $333 | $246.23 | +39.2% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $275 | $253.6 | +15.0% | Jul 23, 2026 |
| RBC Capital | Analyst unavailable | $280 | $267.92 | +17.1% | Jul 7, 2026 |
| Evercore ISI | Analyst unavailable | $329 | $241.83 | +37.6% | May 15, 2026 |
| Barclays | Analyst unavailable | $345 | $238.66 | +44.2% | May 11, 2026 |
| Wells Fargo | Analyst unavailable | $326 | $246.14 | +36.3% | May 8, 2026 |
| Jefferies | Analyst unavailable | $262 | $237.35 | +9.5% | Mar 5, 2026 |
| Stifel Nicolaus | Alex Thompson | $332 | $241.38 | +38.8% | Mar 4, 2026 |
| Wolfe Research | Kalpit Patel | $260 | $231.46 | +8.7% | Mar 2, 2026 |
| Cantor Fitzgerald | Li Watsek | $300 | $231.43 | +25.4% | Mar 2, 2026 |
| Evercore ISI | Josh Schimmer | $324 | $234.07 | +35.5% | Mar 2, 2026 |
| Goldman Sachs | Paul Choi | $255 | $233.5 | +6.6% | Mar 2, 2026 |
| Wedbush | Analyst unavailable | $273 | $218.39 | +14.1% | Feb 12, 2026 |
| Oppenheimer | Analyst unavailable | $262 | $217.93 | +9.5% | Feb 12, 2026 |
| Stifel Nicolaus | Alex Thompson | $325 | $218.04 | +35.9% | Feb 12, 2026 |
| Morgan Stanley | Maxwell Skor | $256 | $221.49 | +7.0% | Feb 12, 2026 |
| Barclays | Eliana Merle | $342 | $238.8 | +43.0% | Jan 27, 2026 |
| RBC Capital | Analyst unavailable | $250 | $205.83 | +4.5% | Jan 20, 2026 |
| Wells Fargo | Derek Archila | $330 | $205.83 | +38.0% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $322 | $208.75 | +34.6% | Jan 9, 2026 |
| Stifel Nicolaus | Alex Thompson | $256 | $201.37 | +7.0% | Dec 11, 2025 |
| Cantor Fitzgerald | Li Watsek | $254 | $209.55 | +6.2% | Oct 13, 2025 |
| RBC Capital | Luca Issi | $230 | $191.49 | -3.8% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $180 | $144.08 | -24.7% | Feb 18, 2025 |
| Bank of America Securities | Tazeen Ahmad | $191 | $151.26 | -20.1% | Sep 23, 2024 |
| Evercore ISI | Gavin Clark-Gartner | $205 | $144.97 | -14.3% | Sep 17, 2024 |
| Oppenheimer | Leland Gershell | $190 | $143.9 | -20.6% | Sep 17, 2024 |
| Citigroup | David Lebowitz | $207 | $139.57 | -13.5% | Sep 17, 2024 |
| Wells Fargo | Derek Archila | $289 | $139.57 | +20.8% | Sep 17, 2024 |
| Bank of America Securities | Tazeen Ahmad | $175 | $142.26 | -26.8% | Sep 16, 2024 |
| Goldman Sachs | Paul Choi | $200 | $142.26 | -16.4% | Sep 16, 2024 |
| Citigroup | David Lebowitz | $178 | $118 | -25.6% | Sep 13, 2024 |
| Oppenheimer | Leland Gershell | $180 | $122.4 | -24.7% | Sep 5, 2024 |
| Jefferies | Kelly Shi | $196 | $128.48 | -18.1% | Aug 13, 2024 |
| Stifel Nicolaus | Alex Thompson | $200 | $137.45 | -16.4% | May 30, 2024 |
| Morgan Stanley | Vikram Purohit | $140 | $124.04 | -41.5% | May 15, 2024 |
| Evercore ISI | Josh Schimmer | $191 | $149.89 | -20.1% | Mar 14, 2024 |
| Wells Fargo | Analyst unavailable | $177 | $118.87 | -26.0% | Jan 3, 2023 |
| Morgan Stanley | Analyst unavailable | $148 | $111.47 | -38.1% | Nov 15, 2022 |
| Leerink Partners | Analyst unavailable | $148 | $110.26 | -38.1% | Nov 14, 2022 |
| Wedbush | Analyst unavailable | $164 | $110.26 | -31.4% | Nov 14, 2022 |
| Bank of America Securities | Tazeen Ahmad | $161 | $117.44 | -32.7% | Mar 20, 2022 |
| Citigroup | David Lebovitz | $187 | $112.39 | -21.8% | Feb 28, 2022 |
| Cowen & Co. | Yaron Werber | $136 | $121.7 | -43.1% | Jan 6, 2022 |
| Canaccord Genuity | Michelle Gilson | $196 | $126.68 | -18.1% | Jul 7, 2021 |
| Cantor Fitzgerald | Alethia Young | $201 | $134.4 | -16.0% | Jun 14, 2021 |
Track every rating change on ASND the moment it posts. Free to start.
Start freeGet the ASND recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.